Spots Global Cancer Trial Database for A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)
Official Title: A Randomized, Double-blind and Imitation, Placebo Parallel Control, Multicentre Phase III Study of TQB2450 With or Without Anlotinib as Consolidation Treatment in Subjects With Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer That Have Not Progressed After Prior Concurrent/Sequential Chemoradiotherapy
Study ID: NCT04325763
Conditions
Study Description
Brief Summary: This study is a randomized, double-blind, double-dummy,placebo parallel controlled, multi-centre,phase III clinical trial to evaluate the efficacy and safety of TQB2450 with or without anlotinib compared with placebo as consolidation treatment in subjects with locally advanced/unresectable (Stage III) Non-Small Cell Lung Cancer that has not progressed after prior concurrent/sequential chemoradiotherapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Anhui Chest Hospital, Hefei, Anhui, China
Peking Union Medical College Hospital, Beijing, Beijing, China
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
The First Affiliated Hospital Sun Yat-Sen University, Guangzhou, Guangdong, China
Yuebei People's Hospital, Shaoguan, Guangdong, China
Affiliated Hospital of Guangdong Medical University, Zhangjiang, Guangdong, China
The Fifth Affiliated Hospital Sun Yat-Sen University, Zhuhai, Guangdong, China
Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, China
The Fourth Hospital of Hebei medical University, Shijiazhuang, Hebei, China
Anyang Cancer Hospital, Anyang, Henang, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Hubei Cancer Hospital, Wuhan, Hubei, China
Hunan Cancer Hospital, Changsha, Hunan, China
Xiangya Hospital Central South University, Changsha, Hunan, China
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Huaian First People's Hospital, Huai'an, Jiangsu, China
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
Jiangsu People's Hospital, Nanjing, Jiangsu, China
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Qilu Hospital of Shandong University, Jinan, Shandong, China
Baoji Central Hospital, Baoji, Shanxi, China
Shanxi Cancer Hospital, Taiyuan, Shanxi, China
Xijing Hospital of Airforce Medical University, Xi'an, Shanxi, China
First Affiliated Hospital of Xi'anjiantong University, Xi'an, Shanxi, China
Tianjin Cancer Hospital, Tianjin, Tianjin, China
The first Hospital of Zhengjiang Province, Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Zhejiang Hospital, Hangzhou, Zhejiang, China
Zhejiang People's Hospital, Hangzhou, Zhejiang, China
Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China
Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, China
Taizhou Central Hospital, Taizhou, Zhejiang, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
